Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADP-ribosylation factor-like protein 15 (ARL15)
- Target
- ARL15
- Molecular classification
- Small GTPase, ARF-like protein (ARF family small GTPase), Signaling protein, Other (not a receptor, ion channel, or enzyme by current evidence)
01
Overview
ADP-ribosylation factor-like protein 15 (ARL15) is a member of the ARF family of small GTPases, structurally related to ADP-ribosylation factors but with divergent functions. ARL15 is ubiquitously expressed in human tissues and localizes predominantly to the Golgi apparatus, with additional presence at the plasma membrane and in vesicular compartments. Its key roles include regulation of adipocyte differentiation and adiponectin secretion, mediating intracellular trafficking processes, and acting as a positive regulator of TGFβ family signaling via direct interaction with Smad4, thereby influencing Smad-complex assembly and signaling. Genetic studies have associated ARL15 variants with metabolic syndromes, including insulin resistance, obesity, type 2 diabetes, dyslipidemia, and lipodystrophy, as well as rheumatoid arthritis. Although no approved therapeutic drugs directly target ARL15, its fundamental participation in these pathways make it of significant interest as a potential therapeutic target for metabolic and inflammatory diseases[1][2][3][5].
- Other names
- ARL15ARFRP2ADP-ribosylation factor-related protein 2FLJ20051
02
Biological functions
Intracellular traffickingRegulation of adipogenesis (adipocyte differentiation)Regulation of adiponectin secretionPositive regulation of TGFβ family signaling (interaction with Smad4)Protein-protein interactions (with Smad4, ARL6IP5)
03
Disease associations
Metabolic disease (including insulin resistance, obesity, type 2 diabetes)LipodystrophyRheumatoid arthritisDyslipidemiaPotentially other metabolic syndromes
04
Safety considerations
Loss-of-function may predispose to severe insulin resistance, lipodystrophy, and metabolic dysfunctionPotential impact on adipose tissue development and function
05
Biomarkers
Genetic variants/haploinsufficiency associated with lipodystrophyGenetic association with metabolic syndrome traits (HDL, fasting insulin)Association with rheumatoid arthritis susceptibility
Beyond the preview
Go deeper on ADP-ribosylation factor-like protein 15 (ARL15).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADP-ribosylation factor-like protein 15 (ARL15).